Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT04370054 |
| Consolidated Lead Sponsor | Pfizer |
| Therapeutic Condition Cohort | Rare Genetic, Women's Health, and Other |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | ACTIVE NOT RECRUITING |
| Registered Enrollment | 77 participants (ACTUAL) |
| Registered Start Date | 2020-08-18 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Stanford Health Care and Stanford Cancer Institute | Stanford, CA | Open Hospital Dossier -> |
| UCSF Medical Center and Helen Diller Cancer Center | San Francisco, CA | Open Hospital Dossier -> |
| Fred Hutchinson Cancer Center and UW Medicine | Seattle, WA | Open Hospital Dossier -> |
| The Alfred Hospital | Melbourne, Australia | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.